LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
63.64
+0.56 (0.89%)
Dec 17, 2025, 10:13 AM EST - Market open
LivaNova Revenue
LivaNova had revenue of $357.75M in the quarter ending September 30, 2025, with 12.46% growth. This brings the company's revenue in the last twelve months to $1.35B, up 8.63% year-over-year. In the year 2024, LivaNova had annual revenue of $1.25B with 8.66% growth.
Revenue (ttm)
$1.35B
Revenue Growth
+8.63%
P/S Ratio
2.55
Revenue / Employee
$465,159
Employees
2,900
Market Cap
3.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
| Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
| Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
| Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
| Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
| Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
| Dec 31, 2018 | 1.11B | 94.68M | 9.35% |
| Dec 31, 2017 | 1.01B | 47.42M | 4.91% |
| Dec 31, 2016 | 964.86M | 601.62M | 165.63% |
| Dec 31, 2015 | 363.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LIVN News
- 14 days ago - LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting - Business Wire
- 15 days ago - LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea - Business Wire
- 22 days ago - LivaNova to Present at Piper Sandler Healthcare Conference in December - Business Wire
- 23 days ago - LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services - Business Wire
- 4 weeks ago - LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day - Business Wire
- 5 weeks ago - LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance - Business Wire
- 7 weeks ago - LivaNova to Present at Wolfe Research Healthcare Conference in November - Business Wire